About the Company

## Basic Information

**Company Name:** Mitsubishi Tanabe Pharma Corporation  
**Representative:** President & Representative Director, Michihiro Tsuchiya  
**Capital Stock:** 50 billion yen  
**Employees:** 9,266 (consolidated: end of March 2010)  
**Headquarters:** 2-6-18 Kitahama, Chuo-ku, Osaka 541-8505, Japan  
**Date of Merger:** October 1, 2007  
**Business description:** Manufacture and sale of pharmaceuticals, centered on ethical pharmaceuticals

### Group Companies

#### Domestic:
- Mitsubishi Tanabe Pharma Factory Ltd.
- Tanabe Seiyaku Yoshiki Factory Co., Ltd.
- Benesis Corporation
- BIPHA CORPORATION
- API Corporation
- Sun Chemical Co., Ltd.
- Yoshitomiyakuhin Corporation
- Tanabe Seiyaku Hanbai Co., Ltd.
- Choseido Pharmaceutical Co., Ltd.
- Tanabe R&D Service Co., Ltd.
- Tanabe Total Service Co., Ltd.
- MP-Logistics Corporation

#### Network

**Headquarters:** Tokyo Head Office  
**Sales Network:**  
Hokkaido Branch, Tohoku Branch, Kita-Kanto Branch, Koshinetsu Branch, Tokyo Branch, Chiba Branch, Saitama Branch, Yokohama Branch, Tokai Branch, Kyoto Branch, Osaka Branch, Kobe Branch, Chugoku Branch, Shikoku Branch, Kyushu Branch  
**Research Centers:**  
Toda Office, Kazusa Office, Yokohama Office, Kashima Office (Osaka)

**Overseas Network:** Shanghai Office

### Overseas:

#### United States
- Mitsubishi Tanabe Pharma Holdings America, Inc.
- Tanabe Research Laboratories U.S.A., Inc.
- Mitsubishi Tanabe Pharma Development America, Inc.
- Mitsubishi Tanabe Pharma America, Inc.
- Tanabe U.S.A., Inc.
- MP Healthcare Venture Management, Inc.

#### Europe
- Tanabe Europe N.V.
- Mitsubishi Pharma Europe Ltd.
- Mitsubishi Pharma Deutschland GmbH
- Synthelabo-Tanabe Chimie S.A.

#### Asia
- Tianjin Tanabe Seiyaku Co., Ltd.
- Mitsubishi Pharma (Guangzhou) Co., Ltd.
- Mitsubishi Pharma Research & Development (Beijing) Co., Ltd.
- Guangdong Tanabe Pharmaceutical Co., Ltd.
- Taiwan Tanabe Seiyaku Co., Ltd.
- Tai Tien Pharmaceuticals Co., Ltd.
- P.T. Tanabe Indonesia
- Mitsubishi Tanabe Pharma Korea Co., Ltd.

### Major Ethical Drugs

#### Cardiovascular Drugs
- Arplag (anti-platelet),  
- Tanatri (anti-hypertensive),  
- Herbesser (anti-anginal and anti-hypertensive),  
- Sermon (cerebral circulation and metabolism ameliorator),  
- Maintate (anti-hypertensive, anti-anginal, and anti-arrhythmic),  
- Liple (chronic arterial occlusion/circulatory disturbance)

#### Biological Products
- Remicade (anti-rheumatoid arthritis, Crohn's disease, anti-refractory uveoretinitis by Bechet's disease, psoriasis, ankylosing spondylitis, Ulcerative colitis),  
- Venoglobulin-IH (intravenous human immunoglobulin),  
- Neuart (anticoagulant)

#### CNS Drugs
- Radicut (cerebral neuroprotectant),  
- Ceredist (anti-spinocerebellar degeneration),  
- Depas (anxiolytic agent)

#### Gastrointestinal Drugs
- Urso (agent for improving hepatic, biliary, and digestive functions),  
- Omeprazone (proton pump inhibitor),  
- Gastrom (anti-gastritis and anti-gastric ulcer)

#### Allergy/Respiratory Drugs
- Talion (anti-allergic disorders),  
- Theodur (bronchodilator)

### OTC Products
- Aspara (drinks, mini-drinks, vitamin preparations, and eyedrops),  
- Nan Pao (herbal medicine, mini-drinks),  
- Smart-Eye (eyedrops),  
- Digestive medicine Agents for treating skin conditions

### Others
- Manufacture and sale of fine chemicals and active pharmaceuticals ingredients / intermediates
Explanation of Terms

**Informed Consent**
A process in which the doctor provides the patient with adequate information on the medical care content, and obtains consent from said patient.

**Evidence**
Proof or verification based on scientific data on the efficacy of a treatment method for certain disease symptoms.

**Ordering System**
Information communication system that computerizes some tasks in the medical front to realize labor-saving in hospital procedures and timesaving upon provision of services. By inputting instructions for prescriptions and examinations, which hitherto had been provided orally from physicians, the said instruction can be coordinated with tasks in relative departments, enabling speedy handling and processing in all future procedures from medical care and examination to medical billing.

**Orphan Drug**
A pharmaceutical drug designed to treat a specific rare disease or disorder. Although there is high medical need for these drugs, the number of patients requiring these drugs is small, and therefore, recovery of investment in research and development for these drugs is difficult.

**Generic Drug**
A drug manufactured using the same formula of an existing drug for which the patent protection for its active ingredients, potency and efficacy have expired, and that contain equivalent active ingredients. The term “generic” encompasses meanings of “common” and “general,” and in the Western world, it is often prescribed by its active ingredients, or “generic names,” instead of its product name. This is why it is referred to as a Generic Drug.

**Self-Medication**
When individuals use products, information, and knowledge related to health and medical care available in their immediate surroundings to maintain and enhance their health or to prevent illnesses, at their own risk. This includes well-informed utilization of OTC (over-the-counter) drugs to prevent or alleviate mild symptoms.

**Proper Use**
When pharmaceuticals are prescribed and prepared in their optimum form in regards to drug selection, formulation, appropriate administration and dosage, based on precise diagnosis. Also, a cycle in which the patient has satisfactory understanding of the above prescribed drug, and after the patient takes the prescribed drug according to instructions, its effects and side-effects are evaluated and reflected onto the subsequent prescription.

**Electronic Chart**
A system where medical charts written by doctors at medical institutions are electronically recorded and stored on computers.

**Pipeline**
A series of processes within the pharmaceutical company that each drug takes from initial development stage to commencement of sales.

**Validation**
Scientific verification and documentation that manufacturing facilities, procedures and processes will yield the desired result, in order to consistently manufacture pharmaceuticals that meet the target quality.

**Phase 2 Study**
Study in secondary phase. Effective and safe usage (method of administration, number of administration, administration period, administration intervals, etc.) and dosage (the most effective dosage) are deliberated in clinical studies, targeting a relatively small number of patients.

**Phase 3 Study**
Study in tertiary phase. Comparison examination of efficacy and safety with existing medicine and placebo in clinical studies, targeting a large number of patients.

**GCP (Good Clinical Practice)**
Standards for implementation of clinical studies of pharmaceuticals.

**GLP (Good Laboratory Practice)**
Standards concerning implementation of non-clinical studies related to pharmaceutical safety.

**GMP (Good Manufacturing Practice)**
Standards concerning manufacturing control and quality control for pharmaceuticals and non-medicinal products.

**GQP (Good Quality Practice)**
Standards concerning quality control for pharmaceuticals, non-medicinal products, cosmetics, and medical equipment.

**GVP (Good Vigilance Practice)**
Standards concerning post-marketing safety management of pharmaceuticals, non-medicinal products, cosmetics, and medical equipment.

**MR (Medical Representative)**
Person in charge of medical information. As the person in charge of sales at pharmaceutical companies, an MR visits medical institutions and provides and collects information regarding quality, efficacy, safety, etc. of pharmaceuticals so as to ensure proper use of pharmaceuticals.

**OTC Drug**
Drugs that can be purchased at pharmacies and drug stores without a prescription from a doctor. They are called OTC (over-the-counter) drugs because they can be purchased over a pharmacy counter.

**QOL (Quality of Life)**
A concept which evaluates whether a person is living his/her day-to-day life with a sense of fulfillment and contentment.